Instil Bio, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Instil Bio, Inc. (TIL) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$1.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- Instil Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$1.65M, a 129.28% decline year-over-year.
- Instil Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $5.65M.
- Instil Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$5.15M.
- Instil Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$15.67M, a 167.66% decline year-over-year.
- Instil Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$3.85M, a 11769.70% decline from fiscal 2024.
- Instil Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $33.00K.
- Instil Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$32.82M, a 624.01% decline from fiscal 2022.
- Instil Bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $6.26M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.00M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$1.65M 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | -$3.85M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | -$4.59M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | -$2.86M 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | $5.65M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $33.00K 10-K · filed 2026-03-27 | |||
| 2024-09-30 | -$4.00M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$3.84M 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | -$5.15M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$32.82M 10-K · filed 2025-03-04 | |||
| 2023-09-30 | -$33.39M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | -$20.69M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$15.67M 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $6.26M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $4.24M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $5.02M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $23.15M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$203.37M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | -$220.74M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $325.27M 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | $367.85M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $232.31M 10-K · filed 2022-03-07 | |||
| 2020-09-30 | $161.33M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $172.76M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$3.56M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |